Podocyte mPGES-2 drives renal aging through prostaglandin E2 signaling, disrupting kidney function and bone homeostasis. Genetic deletion or pharmacological inhibition of mPGES-2 extends healthspan, restores kidney architecture, and reverses age-related osteoporosis in aged mice, suggesting a viable therapeutic target for age-related organ dysfunction.
Key Points
- mPGES-2 in podocytes directly promotes kidney senescence via PGE2/EP1 signaling
- Inhibiting mPGES-2 restores renal endocrine function, raising calcitriol and α-klotho levels
- Pharmacological mPGES-2 inhibition improved bone microarchitecture without adverse effects
Longevity Analysis
Renal aging operates as a systemic driver of dysfunction—its progression undermines endocrine signaling that extends far beyond kidney filtration capacity. This research identifies a specific molecular mechanism linking kidney senescence to bone deterioration, revealing that podocyte health directly determines calcium homeostasis and skeletal integrity. The fact that both genetic and pharmacological approaches tolerate well suggests a therapeutic pathway that addresses a root cause of multisystem aging rather than treating downstream symptoms in isolation. Restoring renal endocrine function at this level could shift the trajectory of age-related osteoporosis and kidney disease simultaneously.
Original published by Wiley Aging Cell, by Dandan Zhong, Chang Hao, Mengyue Li, Jing Liu, Zheng Xu, Jianteng Zhou, Lu Zhao, Siyu Ni, Zhenchao Hu, Yue Sun, Yingying Zou, Dong Sun, Hao Guo, Zhanjun Jia, Dong Guo, Jun‐Li Cao, Ying Sun .